Biowaiver based on biopharmaceutics classification system: Considerations and requirements

Area of Science:

• Pharmaceutical Sciences
• Regulatory Science

Background:

• Biowaivers permit waiving bioequivalence studies for regulatory drug approval, reducing costs and time.
• Biopharmaceutical Classification System (BCS) studies are crucial for biowaiver approval in major markets.
• Regulatory agencies typically favor BCS Class I and III drugs due to high solubility and permeability.

Purpose of the Study:

• To review the prerequisites and guidelines for biowaiver approval.
• To discuss the expanded scope of biowaiver acceptance by the World Health Organization (WHO).
• To cover biowaiver considerations for generic products, topical systems, oral films, and BCS Class II and IV drugs.

Main Methods:

• Review of regulatory guidelines for biowaiver applications.
• Analysis of Biopharmaceutical Classification System (BCS) criteria for drug product approval.
• Examination of WHO's expanded biowaiver acceptance criteria.

Main Results:

• Biowaivers are granted for drug products meeting specific solubility, diffusion, and permeability requirements.
• The WHO has broadened biowaiver acceptance to encompass all BCS drug classes.
• Guidelines are presented for various dosage forms and BCS classes.

Conclusions:

• Biowaiver implementation offers significant time and cost savings in drug development.
• The expanded WHO guidelines facilitate broader application of biowaivers.
• Understanding biowaiver prerequisites is essential for efficient generic drug approval.